In a recent report at the 2018 ASH Annual Meeting, CD19-targeted CAR T cells were administered to 83 patients with R/R ALL with a median age of 10 years (range 2–61) [87]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.